top of page

Selank 10MG

$105.00Price
Excluding Sales Tax
Heptapeptide tuftsin analog studied for anxiolytic and nootropic effects. Potential benefits include reduced anxiety, improved focus and modulation of BDNF and GABAergic pathways. Most data are preclinical or small clinical cohorts; broader, independent trials are needed.
Quantity

  • Selank – Research & Chemical Profile

    Description

    Selank is a synthetic heptapeptide and tuftsin analogue with the sequence Thr–Lys–Pro–Arg–Pro–Gly–Pro (TKPRPGP). It has been investigated as an anxiolytic and nootropic agent. Preclinical and limited clinical studies report effects on GABAergic signaling, monoamine metabolism, immune‑cytokine balance, and rapid increases in brain‑derived neurotrophic factor (BDNF) expression.

     

    Chemical Structure / Identifiers

    Property

    Detail

    Sequence

    Thr–Lys–Pro–Arg–Pro–Gly–Pro (TKPRPGP)

    Molecular Formula

    C33H57N11O9

    Molecular Weight

    ≈ 751.9 g/mol

    CAS Number

    129954‑34‑3

    PubChem CID

    11765600

    UNII

    TS9JR8EP1G

    Synonyms

    Selanc; threonyl‑lysyl‑prolyl‑arginyl‑prolyl‑glycyl‑proline

     

    Primary Research Focus

    • Anxiolytic and nootropic actions: reduced anxiety‑like behavior and improved cognition in animal models; exploratory clinical work in anxiety disorders.
    • Neurotransmission: modulation of GABAergic genes and potential allosteric effects on GABA_A‑related pathways; effects on monoamine metabolism have been reported.
    • Neurotrophic/BDNF: rapid elevation of hippocampal BDNF expression in rodents.
    • Immunomodulation: shifts in cytokine profiles (e.g., IL‑6) and T‑helper balance described in preclinical studies.

     

    Safety / Limitations

    • Research Use Only outside approved jurisdictions; not cleared by major regulators for disease treatment.
    • Evidence base includes many studies from a single research program; large, independent randomized trials are limited.
    • Reported adverse effects are generally mild (e.g., local nasal irritation in intranasal studies), but long‑term safety and optimal dosing remain uncertain.

     

    Key Publications / References

    Wikipedia summary (identifiers, sequence): https://en.wikipedia.org/wiki/Selank

    PubChem Compound Summary: Selank (CID 11765600). https://pubchem.ncbi.nlm.nih.gov/compound/11765600

    Volkova A et al. Selank administration affects expression of genes involved in neurotransmission and GABAergic signaling. Front Pharmacol. 2016. PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC4757669/

    Vyunova TV et al. Molecular aspects of heptapeptide Selank biological activity (review). 2018. PubMed: https://pubmed.ncbi.nlm.nih.gov/30255741/

    Kolik LG et al. Selank protects against ethanol withdrawal‑induced anxiety/memory disturbances in rats. 2019. PubMed: https://pubmed.ncbi.nlm.nih.gov/31625062/

    NCATS/UNII registry entry for Selank (TS9JR8EP1G). https://gsrs.ncats.nih.gov/ginas/app/beta/substances/TS9JR8EP1G

     

    Disclaimer: For research background only. Not medical advice. Selank is not approved for diagnosis, treatment, or prevention of disease.

bottom of page